GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » PS Ratio

Coya Therapeutics (Coya Therapeutics) PS Ratio : 13.78 (As of Jun. 02, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Coya Therapeutics's share price is $7.62. Coya Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.55. Hence, Coya Therapeutics's PS Ratio for today is 13.78.

The historical rank and industry rank for Coya Therapeutics's PS Ratio or its related term are showing as below:

COYA' s PS Ratio Range Over the Past 10 Years
Min: 10.97   Med: 15.2   Max: 18.62
Current: 13.78

During the past 4 years, Coya Therapeutics's highest PS Ratio was 18.62. The lowest was 10.97. And the median was 15.20.

COYA's PS Ratio is ranked worse than
59.12% of 998 companies
in the Biotechnology industry
Industry Median: 9 vs COYA: 13.78

Coya Therapeutics's Revenue per Sharefor the three months ended in Mar. 2024 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.55.

Back to Basics: PS Ratio


Coya Therapeutics PS Ratio Historical Data

The historical data trend for Coya Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics PS Ratio Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - 12.54

Coya Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - 12.54 17.94

Competitive Comparison of Coya Therapeutics's PS Ratio

For the Biotechnology subindustry, Coya Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coya Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's PS Ratio falls into.



Coya Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Coya Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=7.62/0.553
=13.78

Coya Therapeutics's Share Price of today is $7.62.
Coya Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.55.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Coya Therapeutics  (NAS:COYA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Coya Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coya Therapeutics (Coya Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Executives
Dieter Weinand director C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md director
Adrian Hepner officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder officer: Chief Financial Officer ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman director, 10 percent owner, officer: Chief Executive Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc 10 percent owner 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057

Coya Therapeutics (Coya Therapeutics) Headlines

From GuruFocus